NICE green light for immunotherapy Bavencio
Merck and Pfizer’s drug will now be available on the NHS in combination with axitinib as a first-line treatment for kidney cancer
Read Moreby Selina McKee | Sep 2, 2020 | News | 0
Merck and Pfizer’s drug will now be available on the NHS in combination with axitinib as a first-line treatment for kidney cancer
Read Moreby Selina McKee | Aug 28, 2020 | News | 0
NICE says the combination’s cost-effectiveness estimate is higher than what is considered acceptable for NHS use
Read Moreby Anna Smith | Jul 30, 2019 | News | 0
The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorisation.
Read Moreby Anna Smith | Jul 22, 2019 | News | 0
The opinion is for the indication of RCC, the most common kind of kidney cancer found in adults.
Read Moreby Anna Smith | May 15, 2019 | News | 0
The decision was based on positive results from the Phase III JAVELIN Renal 101 study.
Read Moreby Selina McKee | Oct 19, 2018 | News | 0
A pivotal Phase III trial investigating a combination of MSD’s anti-PD-1 therapy Keytruda and Pfizer’s tyrosine kinase inhibitor Inlyta has shown a significant benefit on both overall (OS) and progression-free survival (PFS) in patients with kidney cancer.
Read Moreby Selina McKee | Apr 12, 2018 | News | 0
Pfizer is terminating a late-stage trial assessing Inlyta in patients at risk of kidney cancer recurrence after an interim analysis showed that it was highly unlikely the drug would offer any benefit in this setting.
Read Moreby Selina McKee | Dec 22, 2017 | News | 0
Merck and Pfizer’s avelumab has picked up its second breakthrough therapy status in the US, this time for use in combination with Inlyta for treatment-naïve patients with advanced renal cell carcinoma (RCC).
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
